Unusual false-positive results of whole-body 131I scintigraphy: Four different case scenarios

Document Type: Case Report

Authors

1 Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Students’ Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran

3 Association of Nuclear Medicine and Molecular Imaging (ANMMI), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Abstract

Post-treatment or diagnostic whole-body radioiodine scintigraphy is widely used to assess the residual, recurrence, or metastases of differentiated thyroid carcinoma because of the high sensitivity and accuracy that this assessment provides. While bearing in mind all the diagnostic potential of this test, we have to consider its’ potential pitfalls, as well. Herein, we present 4 patients with differentiated thyroid carcinoma, who received 131I for ablation therapy after having undergone total thyroidectomy. On post-treatment radioiodine scintigraphy, foci of unusual 131I uptake were noted in facial, axillary, inguinal, and renal regions, which were finally either histologically or anatomically diagnosed as papillary oncocytic cystadenoma, ectopic axillary breast tissue, epidydimal cyst, and simple renal cyst, respectively. Such 131I uptake patterns underscore the value of recognizing where and why false-positive uptakes take place and should appreciate the potential causes of false-positive results in whole-body 131I scintigraphy.

Keywords

Main Subjects


  1. Wartofsky L, Van Nostrand D. Thyroid cancer: a comprehensive guide to clinical management:    New York: Springer-Verlag; 2016.
  2. Ahn BC. Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics. 2012;2(4):392-402.
  3. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol. 2006 Oct;155(4):495-512.
  4. Oh J-R, Ahn B-C. False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer. Am J Nucl Med Mol Imaging. 2012;2(3):362–385.
  5. Waxman A, Ramanna L, Chapman N, Chapman D, Brachman M, Tanasescu D, Berman D, Catz B, Braunstein G. The significance of 1-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med. 1981 Oct;22(10):861-5.
  6. Triggiani V, Moschetta M, Giagulli VA, Licchelli B, Guastamacchia E. Diffuse 131I lung uptake in bronchiectasis: a potential pitfall in the follow-up of differentiated thyroid carcinoma. Thyroid. 2012 Dec;22(12):1287-90.
  7. Carlisle MR, Lu C, McDougall IR. The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun. 2003 Jun;24(6):715-35.
  8. Zhao LX, Li L, Li FL, Zhao Z. Rectus abdominis muscle metastasis from papillary thyroid cancer identified by I-131 SPECT/CT. Clin Nucl Med. 2010 May;35(5):360-1.
  9. von Falck C, Beer G, Gratz KF, Galanski M. Renal metastases from follicular thyroid cancer on SPECT/CT. Clin Nucl Med. 2007 Sep;32(9):751-2.
  10. Aide N, Lehembre E, Gervais R, Bardet S. Unusual intratracheal metastasis of differentiated thyroid cancer accurately depicted by SPECT/CT acquisition after radioiodine ablation. Thyroid. 2007 Dec;17(12):1305-6.
  11. Agriantonis DJ, Hall L, Wilson MA. Utility of SPECT/CT as an adjunct to planar whole body I-131 imaging: liver metastasis from papillary thyroid cancer. Clin Nucl Med. 2009 Apr;34(4):247-8.
  12. Jong I, Taubman K, Schlicht S. Bronchiectasis simulating pulmonary metastases on iodine-131 scintigraphy in well-differentiated thyroid carcinoma. Clin Nucl Med. 2005 Oct;30(10):688-9.
  13. Rachinsky I, Driedger A. Iodine-131 uptake in a menstruating uterus: value of SPECT/CT in distinguishing benign and metastatic iodine-positive lesions. Thyroid. 2007 Sep;17(9):901-2.
  14. Avram AM. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med. 2012 May;53(5):754-64.